Sunshine Heart to Present at The Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference

(firmenpresse) - SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN -- (Marketwire) -- 12/01/11 -- Sunshine Heart, Inc. (ASX: SHC), today announced that Jeff Mathiesen, Sunshine Heart's Chief Financial Officer, is scheduled to present at Canaccord Genuity's 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference in San Francisco, CA on Tuesday, December 6th at 9:20AM PST.

A live webcast of the presentation will be available under the Webcast section of the Company's website at .

Sunshine Heart is a global medical device company committed to the commercialization of the C-Pulse Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-Pulse is designed to relieve the symptoms of heart failure through the use of counter-pulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and a reduction in the heart's pumping load. The Company has completed enrollment of an approved U.S. Food and Drug Administration (FDA) 20 patient feasibility clinical trial with the C-Pulse System. Sunshine Heart is a Delaware-based Corporation headquartered in Minneapolis with a subsidiary presence in Australia. The Company has been listed on the ASX since September 2004. For more information, please visit .



For further information, please contact:

Jeff Mathiesen
Chief Financial Officer
Sunshine Heart, Inc.
T: 952 345 4200

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 01.12.2011 - 18:09 Uhr
Sprache: Deutsch
News-ID 93229
Anzahl Zeichen: 0

contact information:
Town:

SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN

Kategorie:

Medical Devices

Diese Pressemitteilung wurde bisher 187 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Sunshine Heart to Present at The Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Sunshine Heart (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Sunshine Heart, Inc. Announces First Patient Implanted in C-Pulse System Europea ...

EDEN PRAIRIE, MN -- (Marketwired) -- 05/09/13 -- Sunshine Heart, Inc. (NASDAQ: SSH) announced today the implant of the first patient in the OPTIONS HF C-Pulse System Multicenter Study. The post market study is intended to treat patients with moderat ...

Sunshine Heart, Inc. Closes Public Offering of Common Shares ...

EDEN PRAIRIE, MN and SYDNEY, AUSTRALIA -- (Marketwired) -- 04/16/13 -- Sunshine Heart, Inc. (NASDAQ: SSH) (ASX: SHC) announced today the closing of its previously announced underwritten public offering of 2,875,000 shares of its common stock, which ...

Sunshine Heart, Inc. Prices $13.1 Million Public Offering of Common Shares ...

EDEN PRAIRIE, MN and SYDNEY, AUSTRALIA -- (Marketwired) -- 04/11/13 -- Sunshine Heart, Inc. (NASDAQ: SSH) (ASX: SHC) announced today the pricing of its previously announced offering of 2,500,000 shares of its common stock at a price to the public of ...

Alle Meldungen von Sunshine Heart